Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming

了解 CD8 T 细胞启动中 DC 许可的机制

基本信息

  • 批准号:
    10630938
  • 负责人:
  • 金额:
    $ 46.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Effective responses to viruses, intracellular pathogens and tumors rely on the successful expansion and arming of cytolytic CD8 T cells from a naïve and quiescent T cell repertoire. This process, called CD8 T cell priming, is dependent on a specialized antigen-presenting cell known as conventional dendritic cells (cDCs). Recent studies from our lab have shown that a specific type of dendritic cells, called cDC1, is responsible for CD8 T cell priming and depends on the transcription factor Batf3 for development. In the process of priming CD8 T cells, the cDC1 captures foreign antigens or tumor-specific neo-antigens, and presents these antigens on the MHC-I molecule in order to stimulate the T cell receptor (TCR) of the CD8 T cell. In the absence of cDC1, such as in Batf3-deficient mice, CD8 T cells are not activated against viruses or tumors. In addition, however, full activation of CD8 T cell requires that cDC1 receive signals that program its ability to fully activate CD8 T cells. This process is called `DC licensing', but is currently not fully characterized. Our recent work has shown that current models for DC licensing are incomplete. Specifically, while we have confirmed the requirement for CD40 signaling in response to CD40L provided by a helper cell, we have shown that the expected target of CD40, CD70, does not explain the beneficial effect of DC licensing for tumor rejection. This result implies that additional targets of CD40 are needed to understand DC licensing. Further, it has been thought that CD4 T cells are the exclusive agent in the licensing process. However, these conclusions derived from older studies and less precise methods. In contrast, we developed an Xcr1-Cre deletor strain to delete genes specifically from cDC1, and found unexpected results, that CD4 T cells are not always critical for cDC1 licensing, suggesting that other cells expressing CD40L may be involved. Further, mechanism by which CD40 signaling induces licensing of the cDC1 is unclear. Several mechanisms have been proposed, but our preliminary data excludes the major proposed mechanism, those invoking CD70, as being critical for the effect of licensed cDC1 in priming CD8 T cells. Our proposal will first test (Aim 1) which Batf3-specific genes expressed in cDC1 are important for cDC1 to support CD8 T cells responses. Second (Aim 2), we will determine identify the targets of CD40 signaling in cDC1 that are required for fully activating CD8 T cells. Finally, in Aim 3, we will test the role of cells that we have identified as alternative sources of CD40 ligand, including iNKT cells and γδ T cells.
摘要 对病毒、细胞内病原体和肿瘤的有效应答依赖于从幼稚和静止T细胞库成功扩增和武装溶细胞性CD 8 T细胞。这一过程称为CD 8 T细胞引发,依赖于一种称为常规树突状细胞(cDC)的特化抗原呈递细胞。我们实验室最近的研究表明,一种特殊类型的树突状细胞,称为cDC 1,负责CD 8 T细胞启动并依赖于转录因子Batf 3进行发育。在启动CD 8 T细胞的过程中, 在细胞中,cDC 1捕获外源抗原或肿瘤特异性新抗原,并将这些抗原呈递到细胞上。 在一些实施方案中,CD 8 T细胞可以与MHC-I分子结合以刺激CD 8 T细胞的T细胞受体(TCR)。在不存在cDC 1的情况下,这样的 在Batf 3缺陷小鼠中,CD 8 T细胞不被激活以对抗病毒或肿瘤。此外,全面 CD 8 T细胞的活化需要cDC 1接收信号,该信号对其完全活化CD 8 T细胞的能力进行编程。 这一过程被称为“发展中国家许可证发放”,但目前尚未完全确定。我们最近的工作表明, 目前的DC许可模式是不完整的。具体而言,虽然我们已经确认了 CD 40信号对辅助细胞提供的CD 40 L的应答,我们已经表明, CD 40、CD 70不能解释DC许可对肿瘤排斥的有益作用。这一结果意味着, 需要额外的CD 40靶点来理解DC许可。此外,已经认为CD 4 T 细胞是许可过程中的唯一代理。然而,这些结论来自更早的研究, 不太精确的方法。相比之下,我们开发了一种Xcr 1-Cre缺失菌株, 从cDC 1,并发现了意想不到的结果,CD 4 T细胞并不总是cDC 1许可的关键,这表明其他细胞表达CD 40 L可能参与。此外,CD 40信号传导诱导 cDC 1的许可尚不清楚。已经提出了几种机制,但我们的初步数据排除了 主要提出的机制,那些调用CD 70,作为关键的许可的cDC 1在启动CD 8 T细胞的效果。我们的建议将首先测试(目标1)在cDC 1中表达的哪些Batf 3特异性基因是重要的 cDC 1支持CD 8 T细胞应答。第二(目标2),我们将确定识别CD 40的靶点 cDC 1中的信号传导是完全激活CD 8 T细胞所需的。最后,在目标3中,我们将测试细胞的作用 我们已经鉴定为CD 40配体的替代来源,包括iNKT细胞和γδ T细胞。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kenneth M Murphy其他文献

Competition for cytokines: Treg cells take all
细胞因子的竞争:调节性 T 细胞独占鳌头
  • DOI:
    10.1038/ni1207-1285
  • 发表时间:
    2007-12-01
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    Alexander Scheffold;Kenneth M Murphy;Thomas Höfer
  • 通讯作者:
    Thomas Höfer
Recent progress in type 1 classical dendritic cell cross-presentation - cytosolic, vacuolar, or both?
  • DOI:
    10.1016/j.coi.2023.102350
  • 发表时间:
    2023-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Ray A Ohara;Kenneth M Murphy
  • 通讯作者:
    Kenneth M Murphy

Kenneth M Murphy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kenneth M Murphy', 18)}}的其他基金

Transcriptional basis of embryonic macrophage development
胚胎巨噬细胞发育的转录基础
  • 批准号:
    10531441
  • 财政年份:
    2022
  • 资助金额:
    $ 46.68万
  • 项目类别:
Molecular Basis of cDC1 Development
cDC1 开发的分子基础
  • 批准号:
    10450553
  • 财政年份:
    2022
  • 资助金额:
    $ 46.68万
  • 项目类别:
Molecular Basis of cDC1 Development
cDC1 开发的分子基础
  • 批准号:
    10649736
  • 财政年份:
    2022
  • 资助金额:
    $ 46.68万
  • 项目类别:
Transcriptional basis of embryonic macrophage development
胚胎巨噬细胞发育的转录基础
  • 批准号:
    10654858
  • 财政年份:
    2022
  • 资助金额:
    $ 46.68万
  • 项目类别:
Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming
了解 CD8 T 细胞启动中 DC 许可的机制
  • 批准号:
    10211694
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming
了解 CD8 T 细胞启动中 DC 许可的机制
  • 批准号:
    10411993
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
Mechanism of c-MYC repression by IRF8 in myeloid lineages
IRF8 在骨髓谱系中抑制 c-MYC 的机制
  • 批准号:
    10379675
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
Mechanism of c-MYC repression by IRF8 in myeloid lineages
IRF8 在骨髓谱系中抑制 c-MYC 的机制
  • 批准号:
    10493389
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
Function of Wdfy4 in cross-presentation and immunity
Wdfy4在交叉呈递和免疫中的功能
  • 批准号:
    10203752
  • 财政年份:
    2019
  • 资助金额:
    $ 46.68万
  • 项目类别:
Function of Wdfy4 in cross-presentation and immunity
Wdfy4在交叉呈递和免疫中的功能
  • 批准号:
    10430144
  • 财政年份:
    2019
  • 资助金额:
    $ 46.68万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 46.68万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 46.68万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 46.68万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 46.68万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 46.68万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 46.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了